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ABSTRACT
We define phosphovariants as genetic variations
that change phosphorylation sites or their interact-
ing kinases. Considering the essential role of phos-
phorylation in protein functions, it is highly likely
that phosphovariants change protein functions.
Therefore, a comparison of phosphovariants
between individuals or between species can give
clues about phenotypic differences. We categorized
phosphovariants into three subtypes and developed
a system that predicts them. Our method can be
used to screen important polymorphisms and help
to identify the mechanisms of genetic diseases.
INTRODUCTION
Protein phosphorylation is involved in various important
processes: development and learning at the organism level,
and the cell cycle, diﬀerentiation and apoptosis at the cel-
lular level (1,2). Phosphorylation can change the subcellu-
lar localization of a protein, its life span and its aﬃnity for
other proteins or DNA (3). Therefore, the addition or
deletion of phosphorylation sites through phosphovar-
iants can lead to functional variations in proteins that
can result in phenotypic variations or genetic diseases.
By our deﬁnition, phosphovariants are variations that
change phosphorylation sites or their interacting kinases.
We propose three subtypes of phosphovariants. First,
some variations occur directly at phosphorylation sites,
and these sites will be removed if the phosphoreceptors
are replaced with amino acids other than serine, threonine
or tyrosine. Conversely, replacement of another amino
acid with a serine, threonine or tyrosine may add a new
phosphorylation site. Second, variations adjacent to phos-
phorylation sites can result in the removal or addition of
phosphorylation sites. Third, variations may change the
kinases that recognize phosphorylation sites, without
changing the phosphorylation site itself. We divided phos-
phovariants into type I, II and III, respectively, according
to the above descriptions (Figure 1).
We developed PredPhospho (version 2), a web-based
computer program that predicts phosphorylation sites,
and PhosphoVariant, a database for human phosphovar-
iants. Even the advanced laboratory techniques used to
analyze phosphorylation sites, such as mass spectrometry
(MS), cannot analyze all types of proteins (4,5). For exam-
ple, peptides that are either too small or too large in mass
can be easily missed. Moreover, membrane proteins
cannot be obtained in suﬃcient quantities for analysis
(5). Even when proteins can be analyzed with MS, it is
very time consuming and expensive to make thousands
of variant proteins and select the phosphovariants.
PredPhospho can predict the phosphorylation sites in
kinase-speciﬁc ways, using the support vector machines
(SVMs) derived from statistical learning theory proposed
by Vapnik and Chervonenkis in 1995 (6). In our study, we
searched for known phosphovariants and tried to predict
other possible phosphovariants among human variations.
METHODS
PredPhospho
We created classiﬁers of various kinases by training SVMs
with phosphorylation site sequences and nonphosphory-
lated site sequences. In other words, our classiﬁers deter-
mine whether serine, threonine or tyrosine residues within
a sequence can be phosphorylated or not. ‘Phosphorylated
site sequences’ refers to peptide sequences with a serine,
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which are phosphorylated. Conversely, ‘nonphosphory-
lated site sequences’ are sequences with a serine, threonine
or tyrosine residue located at the center, which have
not been found, yet, to be phosphorylated. We obtained
phosphorylated site sequences from public databases: the
Swiss-Prot (release 54.8) and the Human Protein Resource
Database (HPRD, release 7). Nonphosphorylated site
sequences were taken from laboratory data conﬁrmed by
MS (see Supplementary Data).
Manning et al. (7) found 518 human protein kinase
genes in the human genome sequence, using the hidden
Markov model (HMM) proﬁle, and conﬁrmed the identi-
ties of more than 90% of the identiﬁed kinase genes using
cDNA cloning. They also classiﬁed the protein kinase
superfamily into nine broad groups, and subdivided the
groups into 134 families and 204 subfamilies, using
sequence comparisons of the kinase catalytic domains.
We classiﬁed the phosphorylated site sequences according
to their kinases and created the classiﬁers in a kinase-
speciﬁc manner. Because of the limitations of the phos-
phorylated sequence data presently available in public
databases, we can make classiﬁers for only six kinase
groups: AGC, CAMK, CK1, CMGC, STE and TK; and
18 kinase families: AKT, CAMK2, CAMKL, CDK, CK1,
CK2, GSK, IKK, JakA, MAPK, PDGFR, PIKK, PKA,
PKC, RSK, Src, STE20 and Syk (all abbreviations are
shown in the footnote to Supplementary Table S1). The
detailed algorithms and methods were described in the
Supplementary Data.
Evaluation ofthe system
The performance status of the prediction for each kinase
group and family is shown in Supplementary Table S2.
The performance of the prediction with combinations of
all the kinase group models or all the family group models
is not the numerical multiplication of the performance of
each model. Therefore, to evaluate the performances of
the predictions at the kinase group level or at the family
level, we tested two proven real data sets, which were
compiled with MS experiments. Data set I was created
by Olsen et al. (5), who identiﬁed phosphorylation sites
in proteins from HeLa cells and classiﬁed the phosphor-
ylation sites according to their deﬁnition. Four classes
are based on their localization probabilities: <0.25,
0.25 <0.75 without kinase motifs, 0.25 <0.75 with
kinase motifs and  0.75. We used only monophosphopep-
tides that had localization probabilities of at least 0.75.
Data set II was derived from the paper of Beausoleil
et al. (4) and we used those of their phosphopeptides
with a localization certainty of >99.4% (see Supplemen-
tary Figure S2). We selected phosphorylation sites and
nonphosphorylated sites from these two data sets. To
avoid overestimating the performance of PredPhospho,
we discarded sequences that were more than 70% identical
to sequences used for training PredPhospho to sequences
used for training PredPhospho (Table 4). We also avoided
using false nonphosphorylated sites by omitting those sites
that are listed as phosphorylation sites in Swiss-Prot or
HPRD. We tested the two kinds of data sets not only with
our PredPhospho, but also with Scansite.
Prediction of phosphovariants
We extracted information about human genetic varia-
tions from SwissVariant of the Swiss-Prot database.
SwissVariant includes single amino acid polymorphisms
and missense mutations (8). The number of variations
listed in SwissVariant was 33651. We consulted the
Swiss-Prot database and HPRD about their eﬀects, and
the references to these variations and phosphorylation
sites. With PredPhospho and Scansite, we predicted the
phosphorylation sites and related kinases for the original
sequences and the variant sequences. The phosphovariants
could be identiﬁed when the phosphorylation sites or
interacting kinases were altered between the original
sequence and the variant sequence. If the phosphorylation
site is in the same location as the variation, it is type I. In
type II phosphovariants, the variation is not in the same
location as the phosphorylation site. We added the symbol
(+) to types I and II when the phosphovariants added
new phosphorylation sites, and (–) when the phosphovar-
iants removed phosphorylation sites [e.g. type I (+) or
type I (–)]. Type III phosphovariants are caused by
changes in the types of kinases involved, rather than in
the phosphorylation site itself, regardless of the locations
of the variations. One variation can include more than one
class of phosphovariant, because one variation can aﬀect
two or more phosphorylation sites. We predicted phos-
phovariants at the kinase group level and the family
level. The predictions at the family level are more sensi-
tive, but less speciﬁc, than those at the group level. To
minimize false negatives, we varied the speciﬁcity options
(95%, 97%, 98% or 99%) according to the speciﬁcity of
each model (Supplementary Table S3). The speciﬁcity
options are described in the Supplementary Data.
Sequence logos
We obtained 562 phosphorylation site sequences recog-
nized by the CMGC kinase group from Swiss-Prot
and HPRD. We trimmed the sequences as six symmetric
Figure 1. Schematic illustration of phosphovariants according to their
types.
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sequences and obtained a sequence logo using the web
program (http://weblogo.berkeley.edu/logo.cgi).
WWW programs
The PredPhospho (version 2) and PhosphoVariant were
implemented using the PERL (version 5.8.8) program-
ming language and MySQL (version 5.0.18). The
PhosphoVariant is a database for the deﬁnite and possible
human variants changing phosphorylation sites and their
interacting kinases. They are available at: http://phospho
variant.ngri.go.kr/seq_input_predphospho2.htm and
http://phosphovariant.ngri.go.kr, respectively.
Bug ﬁxing and minor changes of database will be done,
whenever needed. The new version of Swiss-Prot and
HPRD will be incorporated into our database, annually
at least.
RESULTS
Type I phosphovariants
The substitution of phosphoreceptor amino acids with
amino acids other than serine, threonine or tyrosine
causes the elimination of phosphorylation sites and can
be classiﬁed as type I (–) phosphovariants according to
our classiﬁcation. We found 50 type I phosphovariants
by matching the locations of the variations and those of
phosphorylation sites registered in the Swiss-Prot data-
base and the Human Protein Resource Database
(HPRB, Table 1) (9,10). Of these phosphovariants,
19 are known to cause Mendelian-inherited diseases and
18 are associated with cancers. Another 13 phosphovar-
iants are polymorphisms.
Conversely, new phosphorylation sites can be created
by variations and we deﬁned these as type I (+) phospho-
variants. We found an example in the study of Nousiainen
et al. (11) The cell line that they used had a Gly766Ser
mutation in the probable ATP-dependent RNA helicase
DDX27 (Swiss-Prot ID, Q96GQ7), which was identiﬁed
as phosphorylated. Similarly, the polymorphisms in
Tables 1–3 are good examples of the addition of phos-
phorylation sites by sequence variations. For example, if
we postulate that the isoleucine at amino acid 571 of CTP
synthase 1 (Swiss-Prot ID, P17812) is changed to serine,
then it also represents a type I (+) phosphovariant, rather
than a type I (–) phosphovariant (Table 1).
Type II phosphovariants
It is more diﬃcult to ﬁnd examples of type II phosphovar-
iants than to ﬁnd type I phosphovariants, because we
cannot deﬁnitely say that a phosphorylation site is chan-
ged by a substitution near a phosphorylation site.
However, when some kinases (although not all kinases)
recognize phosphorylation sites, the speciﬁc amino acids
near the phosphoreceptor are important. In Figure 2, we
present sequence logos of phosphorylation site sequences
for the CMGC kinase group. The proline residues at posi-
tion +1 relative to the phosphorylation sites are impor-
tant in the phosphorylation site sequences of the CMGC
kinase group, especially the CDK kinase family and the
MAPK kinase family. Most (84%) of the phosphorylation
sites of the CMGC group registered in the Swiss-Prot
database and the Human Protein Resource Database
(91% of the CDK and 87% of the MAPK kinase families)
have +1 proline residues. If the proline is substituted
with another amino acid, it is highly probable that the
adjacent phosphorylation site will be abolished. The phos-
phorylation site at Ser112 of peroxisome proliferator-
activated receptor gamma protein (Swiss-Prot ID,
P37231) is eliminated by the Pro113Gln substitution
(12). We found three other polymorphisms that abolish
phosphorylation sites of the CMGC kinase group, but
the removal of these phosphorylation sites has not yet
been conﬁrmed (Table 2). The presence of speciﬁc amino
acids does not directly aﬀect phosphorylation by kinases
other than those of the CMGC kinase group, but
sequences near the phosphorylation site must be consid-
ered. Kinases recognize the residues surrounding the
target phosphorylation site, and the amino acids border-
ing phosphorylation sites are, in turn, aﬀected by other
nearby residues (13). Hence, when the relevant kinases
are not members of the CMGC kinase group, it is diﬃcult
to predict type II phosphovariants simply by database
matching, without speciﬁc programs that predict phos-
phorylation sites.
Type IIIphosphovariants
Type III phosphovariants are those variations that
change only the type of kinase involved, without aﬀecting
the phosphorylation site itself. For example, Ser386 of
the tyrosine protein phosphatase, nonreceptor type 1
(PTPN1, Swiss-Prot ID, P18031) is phosphorylated by
cell division cycle 2 (CDC2) kinase, a member of the
CMGC kinase group, and by casein kinase 2 (CK2),
a member of the ‘Other’ kinase group (14,15). The
Pro387Leu substitution reduces 75% of the phosphoryla-
tion by CDC2 in vitro (16). However, it has not been con-
ﬁrmed that Pro387Leu inhibits the recognition of Ser386
by CK2. Only about 5% of the sites phosphorylated by
CK2 that are registered in the Swiss-Prot database or
HPRD have a proline residue at position +1 relative to
the phosphorylation site. There is also no known consen-
sus sequence for CK2 that contains proline at that loca-
tion (17). Therefore, we infer that the proline residue is not
essential for phosphorylation by CK2 and that Pro387Leu
will have little eﬀect on phosphorylation by CK2.
Therefore, we consider Pro387Leu of PTPN1a type III
phosphovariant because it inhibits the recognition of
Ser386 by CDC2 kinase but has little eﬀect on its phos-
phorylation by CK2 (16,18).
Kinases that recognize serine and threonine diﬀer from
the kinases that recognize tyrosine. The substitution
of phosphorylated serine or threonine for tyrosine, or
vice versa, can remove a phosphorylation site or change
the type of kinase that recognizes it. Changes between
serine and threonine can also cause changes in the phos-
phorylation site and the responsive kinase. Therefore, the
phosphovariants in Table 3 (Panel b) are either type I or
type III phosphovariants.
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Gene name
(Swiss-Prot ID)
Variation site
a
(Swiss-Prot
variant ID)
Phosphory-
lation site
Local peptide sequence
b Eﬀect
c Reference(s)
for variation
d
Reference(s)
for phosphor-
ylation site
e
Panel a: Type I( ) phosphovariants
Phosphovariants causing Mendelian inherited disease
EDNRB (P24530) S305N (VAR_003472) S305 CEMLRKK S GMQIALN Hirschsprung disease type 2 8852659 14636059
FANCA (O15360) S858R (VAR_017498) S858 QSRDTLC S CLSPGLI Fanconi anemia 10094191
11091222
17924679
KCNJ1 (P48048) S219R (VAR_019726) S219 RVANLRK S LLIGSHI Bartter syndrome type 2 8841184 8621594
L1CAM (P32004) S1194L (VAR_003947) S1194 AFGSSQP S LNGDIKP Hydrocephalus due to stenosis
of the aqueduct of Sylvius
mental retardation, aphasia,
shuﬄing gait and adducted
thumbs syndrome
8556302
7881431
17081983
MAPT (P10636) S622N (VAR_010350) S622 KHVPGGG S VQIVYKP Frontotemporal dementia
and parkinsonism linked
chromosome 17
10208578 7706316
MAPT (P10636) S637F (VAR_019665) S637 VDLSKVT S KCGSLGN Pick disease 11891833 11104762
9199504
MAPT (P10636) S669L (VAR_019667) S669 DFKDRVQ S KIGSLDN Fatal respiratory
hypoventilation
14595660 11104762
MITF (O75030) S405P (VAR_010302) S405 QARAHGL S LIPSTGL Waardenburg syndrome
type IIa
8589691 10587587
NFKBIA (P25963) S32I (VAR_034871) S32 LLDDRHD S GLDSMKD Autosomal dominant anhidro-
tic ectodermal dysplasia with
immunodeﬁciency
14523047 10882136
9721103
8601309
16319058
10723127
9214631
PER2 (O15055) S662G (VAR_029080) S662 ALPGKAE S VASLTSQ Familial advanced sleep-phase
syndrome
11232563 11232563
PTPN11 (Q06124) Y62D (VAR_015605) Y62 KIQNTGD Y YDLYGGE Patients with Noonan
syndrome 1 manifesting
juvenile myelomonocytic
leukemia
11992261
12325025
12960218
12717436
15951569
15592455
RAF1 (P04049) S259F (VAR_037809) S259 SQRQRST S TPNVHMV Noonan syndrome type 5 17603483 8349614
11997508
11971957
10576742
RAF1 (P04049) T491R (VAR_037819) T491 IGDFGLA T VKSRWSG Noonan syndrome type 5 17603483 11447113
RAF1 (P04049) T491I (VAR_037818) T491 IGDFGLA T VKSRWSG Noonan syndrome type 5 17603483 11447113
RPS6KA3 (P51812) S227A (VAR_006195) S227 DHEKKAY S FCGTVEY Coﬃn–Lowry syndrome 8955270 17192257
STAT3 (P40763) Y657C (VAR_037381) Y657 FAEIIMG Y KIMDATN Hyperimmunoglobulin E
recurrent infection syndrome
autosomal dominant
17881745 15037656
TGFBR2 (P37173) Y336N (VAR_022352) Y336 AKGNLQE Y LTRHVIS Loeys–Dietz aortic aneurysm
syndrome
15731757 9169454
TNNI3 (P19429) S166F (VAR_029454) S166 LGARAKE S LDLRAHL Hypertrophic cardiomyopathy 12974739 11121119
TSC1 (Q92574) T417I (VAR_009403) T417 SLPQATV T PPRKEER Tuberous sclerosis complex,
could be a polymorphism
10570911
10607950
14551205
Phosphovariants found in cancer
CDH1 (P12830) S838G (VAR_001322) S838 LVFDYEG S GSEAASL Ovarian cancer 8075649 10671552
CTNNB1 (P35222) S23R (VAR_017612) S23 PDRKAAV S HWQQQSY Hepatocellular carcinoma,
no eﬀect
10435629
12027456
12027456
CTNNB1 (P35222) S33F (VAR_017617) S33 QQQSYLD S GIHSGAT Pilomatrixoma,
medulloblastoma and
hepatocellular carcinoma
10666372
10435629
10192393
12000790
12114015
11818547
CTNNB1 (P35222) S33L (VAR_017618) S33 QQQSYLD S GIHSGAT Hepatocellular carcinoma 10435629 12000790
12114015
11818547
CTNNB1 (P35222) S37A (VAR_017624) S37 YLDSGIH S GATTTAP Medulloblastoma,
hepatocellular carcinoma
12027456
10435629
10666372
12000790
12114015
11818547
CTNNB1 (P35222) S37C (VAR_017625) S37 YLDSGIH S GATTTAP Pilomatrixoma,
hepatoblastoma
9927029
10192393
12000790
12114015
11818547
CTNNB1 (P35222) S37F (VAR_017626) S37 YLDSGIH S GATTTAP Pilomatrixoma 10192393 12000790
12114015
11818547
(continued)
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Gene name
(Swiss-Prot ID)
Variation site
a
(Swiss-Prot
variant ID)
Phosphory-
lation site
Local peptide sequence
b Eﬀect
c Reference(s)
for variation
d
Reference(s)
for phosphor-
ylation site
e
CTNNB1 (P35222) T41A (VAR_017629) T41 GIHSGAT T TAPSLSG Hepatoblastoma and
hepatocellular carcinoma,
also in a desmoid tumor
12051714
10398436
9927029
12027456
10655994
10435629
12051714
12114015
11818547
12000790
CTNNB1 (P35222) T41I (VAR_017630) T41 GIHSGAT T TAPSLSG Pilomatrixoma and
hepatocellular carcinoma
10192393
10435629
12051714
12114015
11818547
12000790
CTNNB1 (P35222) S45F (VAR_017631) S45 GIHSGAT T TAPSLSG Hepatocellular carcinoma 10435629 12051714
12000790
11955436
CTNNB1 (P35222) S45P (VAR_017632) S45 GATTTAP S LSGKGNP Hepatocellular carcinoma 10435629 12051714
12000790
11955436
FAM10A4 (Q8IZP2) S71L (VAR_023644) S71 DLKADEP S SEESDLE B-cell leukemia, multiple
myeloma, and prostate
cancer
12079276 17081983
MET (P08581) Y1230C (VAR_006292) Y1230 FGLARDM Y DKEYYSV Hereditary papillary renal
carcinoma
9140397 12475979
MET (P08581) Y1230H (VAR_006293) Y1230 FGLARDM Y DKEYYSV Hereditary papillary renal
carcinoma
9140397 12475979
NME1 (P15531) S120G (VAR_004625) S120 GRNIIHG S DSVESAE Neuroblastoma 8047138 8810265
RB1 (P06400) S567L (VAR_005579) S567 SLAWLSD S PLFDLIK Retinoblastoma 10671068
2594029
10207050
TP53 (P04637) T155A (VAR_005901) T155 DSTPPPG T RVRAMAI Esophageal cancer 1868473 12628923
Phosphovariants related with polymorphism
BARD1 (Q99728) S186G (VAR_038371) S186 SYEFVSP S PPADVSE Polymorphism (rs16852741) 15855157
C10orf11 (Q9H2I8) S153F (VAR_033686) S153 SSEDVAS S PERHYTP Polymorphism (rs35349706) 16964243
CTNND1 (O60716) Y217C (VAR_020929) Y217 PDGYSRH Y EDGYPGG Polymorphism (rs11570194) 15592455
16212419
CTPS (P17812) S571I (VAR_027055) S571 RDTYSDR S GSSSPDS Polymorphism (rs17856308) 15489334 16097034
17081983
HIF1A (Q16665) T796A (VAR_015854) T796 ESGLPQL T SYDCEVN Polymorphism (rs1802821) 17382325
INSR (P06213) Y1361C (VAR_015933) Y1361 SYEEHIP Y THMNGGK Polymorphism (rs13306449) 7657032 11401470
KRT36 (O76013) T315M (VAR_020306) T315 EIIELRR T VNALEIE Polymorphism (rs2301354) 17081983
MYH15 (Q9Y2K3) T1125A (VAR_030238) T1125 KTVKELQ T QIKDLKE Polymorphism (rs3900940) 17081983
PDLIM5 (Q96HC4) S136F (VAR_023779) S136 PRPFGSV S SPKVTSI Polymorphism (rs2452600) 17287340
PNN (Q9H307) S671G (VAR_023368) S671 HKSSKGG S SRDTKGS Polymorphism (rs13021) 10095061 17287340
SUB1 (P53999) S11G (VAR_032870) S11 SKELVSS S SSGSDSD Polymorphism (rs17850527) 15489334 17081983
16689930
SRRM2 (Q9UQ35) S883C (VAR_027260) S883 SPDPELK S RTPSRHS Polymorphism (rs17136053) 17287340
TP53 (P04637) S366A (VAR_022317) S366 PGGSRAH S SHLKSKK Polymorphism 9183006
Panel b: Type I(+) phosphovariants
DDX27 (Q96GQ7) G766S S766 ALKQYRA G PSFEERK Unknown 16565220 16565220
aLocations and amino acid changes of the variations in the proteins.
bPeptide sequences with 15-mer amino acids. The amino acids in the eighth position are phosphorylated residues.
cThe meanings or consequences of the variations. We referred to the feature tables of Swiss-Prot for these eﬀects. If the polymorphisms are enrolled in
dbSNP, the IDs of dbSNP are written in the parentheses.
dPubmed ID for the references of the variations
ePubmed ID for the references of the phosphorylation sites
Protein names which are abbreviated by their gene names: epithelial cadherin (precursor), CDH1; catenin b-1, CTNNB1; probable ATP-dependent RNA
helicase DDX27, DDX27; endothelin B receptor (precursor), EDNRB; protein FAM10A4, FAM10A4; Fanconi anemia group A protein, FANCA; ATP-
sensitive inward rectiﬁer potassium channel 1, KCNJ1; keratin, type I cuticular Ha6, KRT36; Neural cell adhesion molecule L1, L1CAM; microtubule-
associated protein tau, MAPT; hepatocyte growth factor receptor (precursor), MET; microphthalmia-associated transcription factor, MITF; NF-k-B
inhibitor a, NFKBIA; nucleoside diphosphate kinase A, NME1; period circadian protein homolog 2, PER2; tyrosine-protein phosphatase nonreceptor
type 11, PTPN11; RAF proto-oncogene serine/threonine-protein kinase, RAF1; retinoblastoma-associated protein, RB1; ribosomal protein S6 kinase alpha-
3, RPS6KA3; signal transducer and activator of transcription 3, STAT3; TGF-beta receptor type-2 (precursor), TGFBR2; cardiac troponin I, TNNI3;
cellular tumor antigen p53, TP53; Hamartin, TSC1.
Nucleic Acids Research,2009, Vol.37, No. 4 1301Performance ofPredPhospho and Scansite
We developed prediction models for six kinase groups
and 18 kinase families. Their accuracy ranged from
70.80 to 94.67% at the kinase family level and
from 71.77 to 91.18% at the kinase group level
(Supplementary Table S2). We tested our prediction
models using two real laboratory data sets compiled
with MS. For the six kinase group models, the sensitivities
were 79.40% with data set I and 75.47% with data set II,
but the speciﬁcities were as low as 60.62% for data set I
and 61.04% for data set II because of the accumulation
of false negatives by all six kinase group models. When
we modiﬁed the speciﬁcity to >95% (see Supplementary
Data for the modiﬁcation of the speciﬁcity for each
model), the speciﬁcities increased to 72.09% and
Table 3. Possible examples of type III phosphovariants
Gene name
(Swiss-Prot ID)
Variation site (Swiss-
Prot variant ID)
Related phos-
phorylation
site (kinase
recognizing it)
Local peptide sequence Eﬀect Reference(s)
for variation
Reference(s) for
phosphorylation
site
Panel a: A possible example of type III phosphovariant
PTPN1 (P18031) P387L (VAR_022014) S386 (CDC2
and CK2)
LRGAQAA S PAKGEPS Low glucose tolerance
and polymorphism
(rs16995309)
15919835 9600099
8491187
Panel b: Possible examples of phosphovariants which can be classiﬁed as type I or III
BRCA1 (P38398) S1217Y (VAR_020695) S1217 ESSEENL S SEDEELP Breast cancer and
breast-ovarian cancer
14722926 17081983
CASP8 (Q14790) S219T (VAR_025816) S219 PREQDSE S QTLDKVY Polymorphism
(rs35976359)
17525332
CDK2 (P24941) Y15S (VAR_016157) Y15 EKIGEGT Y GVVYKAR Polymorphism
(rs3087335)
1396589
12912980
12972555
15144186
CTNNB1 (P35222) S33Y (VAR_017619) S33 QQQSYLD S GIHSGAT Pilomatrixoma 12027456
10192393
12000790
12114015
11818547
CTNNB1 (P35222) S37Y (VAR_017627) S37 YLDSGIH S GATTTAP Hepatocellular
carcinoma
10435629 12000790
12114015
11818547
TEK (Q02763) Y897S (VAR_008716) Y897 GACEHRG Y LYLAIEY Dominantly inherited
venous malformations
10369874 11080633
XRCC1 (P18887) S485Y (VAR_014779) S485 QDNGAED S GDTEDEL Polymorphism
(rs2307184)
15066279
The reasons why these variations are classiﬁed as type III are detailed in the text.
Protein names which are abbreviated by their gene names: breast cancer type 1 susceptibility proteinBRCA1; caspase 8, CASP8; cyclin dependent
kinase 2, CDK2; catenin b-1, CTNNB1; tyrosine-protein phosphatase nonreceptor type 1, PTPN1; angiopoietin-1 receptor (precursorP, TEK;
DNA repair protein XRCC1, XRCC1.
Table 2. Examples of type II( ) phosphovariants
Gene name
(Swiss-Prot ID)
Variation site (Swiss-
Prot variant ID)
Removed phosphorylation
site (related kinases)
Local peptide sequence
a Eﬀect Reference(s)
for variation
Reference(s) for
phosphorylation
site
DUT (P33316) P100S (VAR_022314) S99
b (CDC2) GPETPAI S PSKRARP Polymorphism 17081983
8631817
GJA1 (P17302) P283L (VAR_014101) S282
b (ERK1, ERK2 and
MAPK7)
TAPLSPM S PPGYKLV Polymorphism
(rs2228974)
8631994
9535905
PPARG (P37231) P113Q (VAR_010724) S112
c (ERK2, JNK1 and
MAPK8)
AIKVEPA S PPYYSEK Obesity and
polymorphism
(rs1800571)
9753710 9030579
RXRA (P19793) P261L (VAR_014620) S260
b (ERK2 and MAPK7) NMGLNPS S PNDPVTN Polymorphism
(rs2234960)
12048211
aThe variation sites are underlined and are marked with the bold style.
bThe removals of the phosphorylation sites by the variation have not been conﬁrmed by experiments. However, the removals of the phosphorylation
sites are highly possible because the nearby phosphorylation sites are proved to be recognized by the CMGC group.
cThe removal of the phosphorylation site by the variation has been conﬁrmed by a experiment (12).
If the variations substitute the proline residues at position +1 relative to the phosphorylation sites into other amino acids, the nearby phosphoryla-
tion sites recognized by the CMGC kinase group can be eliminated or the eﬃciency of phosphorylation in that site is signiﬁcantly decreased.
Protein names which are abbreviated by their gene names: deoxyuridine 50-triphosphate nucleotidohydrolase, mitochondrial (precursor), DUT; gap
junction a-1 protein, GJA1; peroxisome proliferator-activated receptor g, PPARG; retinoic acid receptor RXR-a, RXRA.
1302 Nucleic Acids Research, 2009, Vol. 37,No. 472.39%, respectively, for each data set, whereas the sensi-
tivities decreased to 73.24% and 65.76%, respectively
(Table 5). At a speciﬁcity of >99%, the speciﬁcities
changed to 95.79% and 96.62%, respectively, and the
sensitivities to 23.39% and 20.05%, respectively.
Scansite is a widely used web-based prediction software
for phosphorylation sites (19). We also tested Scansite
with the same data sets. When we applied Scansite with
the low-stringency option to the data sets, the
speciﬁcities were 52.60% and 57.06%, respectively, and
the sensitivities were 84.47% and 83.92%, respectively,
whereas with the high-stringency option, the speciﬁcities
were 96.77% and 95.71%, respectively, and the sensitiv-
ities were 16.39% and 13.60%, respectively (Table 6). The
performance of PredPhospho with no modiﬁcation to the
speciﬁcity is similar to that of Scansite used with the low-
stringency option. The performance of PredPhospho with
a speciﬁcity of >99% was similar with that of Scansite
used with the high-stringency option. The data sets were
analyzed in the same way with the 18 kinase family models
(Tables 5 and 6). The family-wise prediction generally had
greater sensitivity and lower speciﬁcity than the group-
wise prediction.
Phosphovariants predicted with PredPhospho andScansite
The numbers of phosphovariants predicted with
PredPhospho and Scansite are shown in Table 7. In the
Supplementary Data, we present the results for phospho-
variants that were predicted with PredPhospho with the
>99% speciﬁcity option. The sensitivity and speciﬁcity of
the prediction of type I phosphovariants will be the same
as the result shown in Table 5, because we can predict
type I phosphovariants simply by the location of phos-
phorylation sites, with no knowledge of the kinds of
kinases involved. The notions of type II and type III phos-
phovariants include the kinds of kinases that recognize the
phosphorylation sites. Therefore, the prediction of type II
and III phosphovariants diﬀers from that of type I. Not
only the phosphorylation site but also the type of kinase
Table 5. The general performance test of the PredPhospho for two real data sets
Speciﬁcity
a Prediction at the group level Speciﬁcity Prediction at the family level
Data I Data II Data I Data II
Sn (%) Sp (%) Sn (%) Sp (%) Sn (%) Sp (%) Sn (%) Sp (%)
No 79.40 60.62 75.47 61.04 No 95.36 29.29 93.60 30.98
95% 73.24 72.09 65.76 72.39 95% 92.68 42.80 88.95 46.63
97% 53.37 80.22 48.31 79.45 97% 88.46 56.81 83.50 57.36
98% 43.11 89.23 38.92 89.26 98% 82.03 66.80 75.44 62.88
99% 23.39 95.79 20.05 96.62 99% 73.18 72.67 66.73 72.39
aOptions of the speciﬁcity. For example, ‘99%’ speciﬁcity option mean cutoﬀ value is adjusted for each model to have 99% speciﬁcity, and ‘No’
speciﬁcity option means each model has default cutoﬀ value without adjustment of speciﬁcity (See supplementary material).
Abbreviations: sensitivity, Sn; speciﬁcity, Sp.
Figure 2. Sequence logos of amino acid sequences near phosphoryla-
tion sites recognized by the CMGC kinase group. The horizontal axis
represents sequential positions relative to the phosphorylation site. The
vertical axis represents decreases in uncertainty. Each letter refers to
an amino acid. As the frequency of an amino acid at a given position
increases, its height increases.
Table 4. The general performance test: the number of each data set
Data I
a Data II
a
(+)
b ( )
b (+) ( )
Ser/Thr
b 1860 926 3017 315
Tyr
b 38 95 359 11
aDiﬀerent data sets compiled with mass spectrometer. See the text for
the detail explanation for data set I and II.
bThe types of amino acids located at the center of peptides. We anno-
tated the peptides as (+) if the Ser/Thr or Tyr at the center of the
peptides is phosphorylated. On contrary, we designated the peptide as
( ) if the center of the peptides is not phosphorylated.
Table 6. The general performance test of the Scansite for two real
data sets
Stringency
a Data I Data II
Sn (%) Sp (%) Sn (%) Sp (%)
Low 84.47 52.60 83.92 57.06
Medium 48.63 85.21 43.81 87.73
High 16.39 96.77 13.60 95.71
aScansite has three levels of stringency: high, medium and low. High
stringency involves low sensitivity and high speciﬁcity, whereas low
stringency involves high sensitivity and low speciﬁcity.
Nucleic Acids Research,2009, Vol.37, No. 4 1303must be identiﬁed, because important amino acid residues
ﬂanking the phosphorylation sites, which guide kinases
to the site, may diﬀer according to the kinase involved.
Therefore, the general performance of our prediction of
type II and type III phosphovariants will be somewhat
diﬀerent from those shown in Table 5. Instead, the perfor-
mance of the each kinase-speciﬁc prediction can be judged
from the performances shown in Supplementary Table S2.
The proportion of phosphovariants predicted by
PredPhospho is shown in Table 8. These data were
selected with the >99% speciﬁcity option at the kinase
family level, and are related to the conﬁrmed phosphory-
lation sites in human or orthologous proteins, for which
kinase information is not yet available. As described in the
Supplementary Data, only phosphorylation sites with
available kinase information were used as training
models for PredPhospho. Hence, the phosphorylation
sites in Table 8 are predicted ones with PredPhospho,
because the phosphorylation sites were not included in
the training data for PredPhospho. If a speciﬁc site is
shown to be a phosphorylation site in human or ortholo-
gous proteins, then the site is deﬁnitely located on the
surface of the protein, and therefore, is accessible to a
kinase. The predicted phosphovariants related to a
proven phosphorylation site are more likely to be true
than are those related to an unproven phosphorylation
site. Numerous phosphorylation sites in humans or
other species are constantly being identiﬁed. The priority
for further research among predicted phosphovariants can
be decided based on the conﬁrmation of speciﬁc phos-
phorylation sites.
DISCUSSION
Changes in phosphorylation sites cause various diseases
by numerous mechanisms. Some proven mechanisms of
the phosphovariants shown in Tables 1–3 are related to
changes in the protein’s aﬃnity for DNA, inducing hyper-
phosphorylation and the inhibition of ubiquitinization.
For example, microphthalmia-associated transcription
factor (MITF) activates the transcription of the tyrosinase
gene. The Ser405Pro change in MITF eliminates the phos-
phorylation site at Ser405 and inhibits the binding
of MITF to DNA. As a result, the mutation causes
Waardenburg syndrome type IIa, the symptoms of
which include depigmentation and sensorineural hearing
loss (20). Abnormal phosphorylation can also cause dis-
ease by increasing phosphorylation at other sites. The
hyperphosphorylation of tau protein induces neuroﬁbril-
lary tangles and the accumulation of these tangles can
result in Alzheimer’s disease and frontotemporal dementia
(FTD). Paradoxically, serine threonine protein kinase N
(PKN) interrupts the phosphorylation of other sites by
phosphorylating Ser637 and Ser669 of tau protein (21).
The mutations Ser637Phe and Ser669Leu of tau protein
eliminate the recognition sites for PKN and induce
the hyperphosphorylation of tau protein. FTD and the
respiratory failure with dementia are known to be related
to Ser637Phe and Ser669Leu, respectively (22,23).
Phosphorylation at Ser32 of NF-kB inhibitor a (Swiss-
Prot ID, P25963) causes ubiquitinization and results in
the activation of NF-kB (24). The Ser32Ile substitution
of NF-kB inhibitor a (Swiss-Prot ID, P25963) eliminates
the phosphorylation site at Ser32. Consequently, the ubi-
quitinization of NF-kB inhibitor a is inhibited by the
Ser32Ile variant of NF-kB inhibitor a and NF-kB
cannot be activated. The Ser32Ile variant of NF-kB inhib-
itor a causes autosomal dominant anhydrotic ectodermal
dysplasia with immunodeﬁciency (25). These are a few
examples of phosphovariants. Considering the numerous
functional roles played by phosphorylation in vivo, there
must be many mechanisms by which phosphovariants can
cause speciﬁc diseases, and these must be identiﬁed.
Some phosphovariants do not cause Mendelian-
inherited diseases, but change an individual’s susceptibility
to disease. The Pro113Gln substitution (dbSNP id,
rs1800571) of peroxisome proliferator-activated receptor
gamma (Swiss-Prot ID, P37231), which eliminates the
phosphorylation site at Ser112, is known to cause obesity
(12). The Pro387Leu substitution (dbSNP ID, rs16995309)
of tyrosine-protein phosphatase nonreceptor, type 1
(Swiss-Prot ID, P18031) is associated with type II
diabetes mellitus (16,18). We only found these two
polymorphic phosphovariants that are related to disease
susceptibility. As shown in Tables 1–3, 21 phosphovar-
iants are polymorphisms, and the biological signiﬁcance
of 19 of these polymorphisms is not yet known. In addi-
tion, we do not know the biological signiﬁcance of most of
the polymorphic phosphovariants predicted in our study.
Considering the importance of phosphorylation in protein
function, polymorphic phosphovariants may well be
involved in speciﬁc diseases or phenotypes.
Apart from the characteristics of the three types of
phosphovariants already suggested, there are other funda-
mental diﬀerences between the type I and other phospho-
variants. Type I phosphovariants completely add or
remove a phosphorylation site because kinases can only
donate a phosphor moiety to an amino acid with a hydro-
xyl group. However, type II and III phosphovariants can
signiﬁcantly aﬀect kinase kinetics without completely
Table 7. The number of the phosphovariants
Speciﬁcity Type I( ) Type I(+) Type II( ) Type II(+) Type III
Panel a: Predicted with PredPhospho at the kinase group level
No 1729 2036 5455 4980 5299
95% 981 1195 1304 1070 986
97% 613 778 694 542 401
98% 314 409 329 213 151
99% 116 150 98 52 21
Panel b: Predicted with PredPhospho at the kinase family level
No 3039 3717 3969 3926 23955
95% 2379 2910 2882 2840 8113
97% 1720 2104 1439 1483 2390
98% 1268 1551 783 862 1213
99% 946 1180 539 548 638
Panel c: Predicted with Scansite
Low 1581 1852 4255 3773 7697
Medium 443 498 487 384 152
High 83 128 35 28 1
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a phosphovariants whose phosphorylation sites were conﬁrmed in human or orthologous proteins
Gene name
(Swiss-Prot ID)
Site (Swiss-Prot
variant ID)
Related phosphorylation
site (predicted kinase
recognizing it
b)
Local peptide sequence Eﬀect Reference(s)
for variation
Reference(s) for
phosphoryla-
tion site
Panel a: Type I( ) phosphovariants
ACIN1 (Q9UKV3) S478F (VAR_022033) S478 (CDK, GSK, and
MAPK)
VQLVGGL S PLSSPSD Polymorphism
(rs3751501)
17242355
(mouse)
c
MECP2 (P51608) S229L (VAR_018200) S229 (MAPK) VKMPFQT S PGGKAEG Polymorphism 10767337
12872250
17046689 (rat)
c
PAH (P00439) S16P (VAR_000869) S16 (RSK and CAMKL) PGLGRKL S DFGQETS Phenylketonuria 1679029
2246858
1301187
7387651 (rat)
c
Panel b: Type II( ) phosphovariants
GTSE1 (Q9NYZ3) R506W (VAR_024154) S504 (PKC) PAPQSLL S ARRVSAL Polymorphism
(rs140054)
10591208 16964243
LIG1 (P18858) P52L (VAR_020194) S51 (CDK and MAPK) GVVSESD S PVKRPGR Polymorphism
(rs4987181)
16964243
Panel c: Type III phosphovariants
Gene name
(Swiss-Prot ID)
Site (Swiss-Prot
variant ID)
Related phosphorylation
site (predicted kinase
recognizing it)
Local peptide sequence Removed kinase
family
d (Added
kinase family
e)
Eﬀect (reference(s)
for variation
f)
Reference(s) for
phosphoryla-
tion site
ABCB11 (O95342) R698H (VAR_035352) S701 (AKT, CAMK2,
CAMKL, IKK, RSK,
and PKC)
SIRQRSK S QLSYLVH AKT, CAMK2, RSK Polymorphism
(16763017)
17242355
(mouse)
c
ABL1 (P00519) P810L (VAR_032678) S809 (GSK and MAPK) MESSPGS S PPNLTPK MAPK Polymorphism
(17344846)
17081983
AQP2 (P41181) P262L (VAR_015255) S261 (IKK and MAPK) RQSVELH S PQSLPRG MAPK Nephrogenic diabe-
tes insipidus
(9550615,
15509592)
16641100 (rat)
c
CASP8 (Q14790) S219T (VAR_025816) S219 (IKK and PIKK) PREQDSE S QTLDKVY IKK Polymorphism
(rs35976359)
17525332
CHGB (P05060) R178Q (VAR_020287) S183 (AKT and GRK) GERGEDS S EEKHLEE AKT Polymorphism
(rs910122)
16807684
EIF4G3 (O43432) P496A (VAR_034009) S495 (MAPK and RSK) QNLNSRR S PVPAQIA MAPK Polymorphism
(rs35176330)
17081983
16964243
MYBPC3 (Q14896) G278E (VAR_019891) S275 (CAMK2, PKA,
PKC, RSK, and STE20)
LSAFRRT S LAGGGRR (CK2) Familial
hypertrophic
cardiomyopathy
type 4 (12707239)
9784245
(chicken)
c
PKMYT1 (Q99640) R140C (VAR_019928) S143 (AKT, CAMKL,
CDK, PKC, and RSK)
YAVKRSM S PFRGPKD AKT Polymorphism
(rs4149796)
17192257
PPP1R12B (O60237) R836K (VAR_024177) S839 (CAMK2, IKK,
and RSK)
ERLSRLE S GGSNPTT CAMK2 and RSK Polymorphism
(rs3881953)
17242355
(mouse)
c
PARK7 (Q99497) E64D (VAR_020493) Y67 (Src) DAKKEGP Y DVVVLPG (PDGFR) Autosomal reces-
sive early-onset
Parkinson disease 7
(15365989
14607841)
15592455
PNN (Q9H307) S671G (VAR_023368) S667 (AKT, GSK, and
IKK)
LERSHKS S KGGSSRD GSK Polymorphism
(rs13021, 10095061)
17287340
SH3PXD2A (Q5TCZ1) R1035Q (VAR_030782) S1038 (AKT, CAMKL,
PIKK, and RSK)
RLAERAA S QGSDSPL AKT and RSK Polymorphism
(rs3781365)
17525332
WDR91 (A4D1P6) L257P (VAR_033358) S256 (IKK and PKC) RNASLSQ S LRVGFLS (MAPK) Polymorphism
(rs292592,
15489334
14702039)
16964243
Eight of the type I( ) phosphovariants (VAR_006195, VAR_023368, VAR_023779, VAR_023644, VAR_030238, VAR_020306, VAR_033686, and
VAR_027260), and a type III phosphovariant (VAR_020695) were also predicted. However, their detail information are already written in Table 1
and 3.
aThe prediction was done with the 99% speciﬁcity option of PredPhospho at the kinase family level.
bKinases that were predicted to recognize the original sequence.
cThe experiment was done in the proteins of other than human. The names of the species are written in the parenthesis.
dRemoved kinases mean that they were predicted not to recognize the variation sequences, while they were predicted to recognize the original
sequences.
eAdded kinases mean that they were predicted to recognized the variation sequences, while they were predicted not to recognize the original
sequences. The added kinases were written in the parentheses.
fThe reference numbers which are started with ‘rs’ are dbSNP ID.
Protein names which are abbreviated by their gene names: Proto-oncogene tyrosine-protein kinase ABL1, ABL1; ATP-binding cassette sub-family B
member 11, ABCB11; Apoptotic chromatin condensation inducer in the nucleus, ACIN1; Aquaporin-2, AQP2; Caspase-8 [Precursor], CASP8;
Secretogranin-1 [precursor], CHGB; Eukaryotic translation initiation factor 4 gamma 3, EIF4G3; G2 and S phase-expressed protein 1, GTSE1;
Zinc ﬁnger protein KIAA1802, KIAA1802; DNA ligase 1, LIG1; Methyl-CpG-binding protein 2, MECP2; Myosin-binding protein C, cardiac-type,
MYBPC3; Phenylalanine-4-hydroxylase, PAH; Parkinson disease protein 7, PARK7; Membrane-associated tyrosine- and threonine-speciﬁc cdc2-
inhibitory kinase, PKMYT1; Pinin, PNN; Protein phosphatase 1 regulatory subunit 12B, PPP1R12B; Ribosomal protein S6 kinase alpha-3,
RPS6KA3; SH3 and PX domain-containing protein 2A, SH3PXD2A; WD repeat-containing protein 91, WDR91.
Nucleic Acids Research,2009, Vol.37, No. 4 1305changing the kinase’s recognition site. For example, the
Pro387Leu substitution of PTPN1 removes only 75% of
the phosphorylation of Ser386 by CDC2 kinase in vitro,
rather than 100% (Table 3) (16).
We can explain phenotypic variations and diseases in
terms of phosphovariants in more cases than we have
anticipated. Of the human proteins registered in the
Swiss-Prot database, 25.5% are phosphoproteins and
60.9% of these phosphoproteins have multiple phosphor-
ylation sites. The protein with the greatest number of
conﬁrmed phosphorylation sites is the serine/arginine
repetitive matrix protein 2 (Swiss-Prot ID, Q9UQ35),
with 195 phosphorylation sites. Although we could only
determine 62 phosphovariants with a database search,
many more phosphovariants must exist. Furthermore, if
we count the mutations that add phosphorylation sites
and the type II and III phosphovariants that cannot be
found without speciﬁc programs, the number of mutations
associated with changes in phosphorylation sites is much
greater. We did not consider haplotypes in this study, for
simplicity. However, if two or more nearby variations are
frequently linked, a nearby phosphorylation site can be
altered, although each variation individually does not
aﬀect the phosphorylation site. Therefore, phosphovar-
iants may account for a much greater proportion of
human variation than we have anticipated.
Several issues must be resolved in future studies. First,
we regarded nonannotated serine, threonine and tyrosine
residues as nonphosphorylated sites. Although we tried
not to select false nonphosphorylated sites by using real
MS data sets, some of the nonphosphorylated sites might
be determined to be phosphorylated sites, in the long run.
Second, type II and type III phosphovariants can be inter-
changed. For example, removed phosphorylation sites
associated with type II (–) phosphovariants predicted
with PredPhospho may be recognized by kinases that
are not included in our prediction models. In such
cases, these variations are type III phosphovariants, not
type II (–). Conversely, if a phosphorylation site is falsely
classiﬁed as a site recognized by multiple kinases, instead
of by one true kinase, and if a variation aﬀects only some
of these kinases, this is a type II phosphovariant incor-
rectly predicted to be a type III phosphovariant. Other
points that must be improved are the low sensitivity
achieved with the high-speciﬁcity option and the low
speciﬁcity achieved with the no-speciﬁcity option of
PredPhospho (Table 5). Moreover, the number of types
of kinases that we can predict must be increased and hap-
lotypes should be considered in future studies.
Our method can be used in pathophysiological studies
of mutations and in the selection of polymorphisms
of clinical and phenotypical importance. Many of the
papers that have described the variations, shown in
Tables 1–3, did not mention that the variations could be
related to changes in phosphorylation sites. This could be
attributable to the lack of a speciﬁc database that connects
mutations with phosphorylation sites, or the lack of a
general understanding of the association between phos-
phorylation and mutation. The type I (+), II and III
phosphovariants we have deﬁned cannot be identiﬁed
simply by database analyses. Speciﬁc programs are
required to identify these phosphovariants. Accordingly,
many nonsense point mutations whose functional
mechanisms are unknown can be reconsidered in terms
of phosphovariant. Furthermore, if some mutations are
predicted to be phosphovariants with our system, further
research will clarify the cause of the associated disease or
protein function. Our system can be used to select mean-
ingful variations among endless numbers of newly identi-
ﬁed polymorphisms. As sequencing techniques advance, a
large number of genetic variations are emerging. At pres-
ent, comparison of whole genomes of individuals is possi-
ble, because the human genome can be sequenced in two
months (26). A comparison of phosphovariants between
individuals or between species can be undertaken before
amino acid variations or nucleic acid variations are com-
pared in whole genomes. A reverse genetic approach for
unknown protein functions or phenotypic variations is
possible with proven phosphovariants. The screening
and prediction of phosphovariants can be a starting
point for further research.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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